Kymera Therapeutics (KYMR) PT Raised to $140 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Price: $108.35 +2.24%
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 92
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 92
Join SI Premium – FREE
JPMorgan analyst Brian Cheng raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $140.00 (from $121.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Citi Opens 90-Day Upside Catalyst Watch on Kymera Therapeutics (KYMR)
- TripAdvisor (TRIP) PT Lowered to $11 at Goldman Sachs
- Saratoga Investment (SAR) PT Lowered to $20 at Oppenheimer
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
